OTC : TKPHF

Takeda Pharmaceutical Company Limited

$34.7 USD

$0 (0.0%)

Volume
200
Average Volume
9.16K
Market Capitalization
$55.2B
P/E Ratio
44.93
Dividend Yield
3.65%
Price Target
Year High
$39.20
Year Low
$26.33
Day High
—
Day Low
—
Payout Ratio
$1.63
Current Ratio
$1.27
Company Overview

OTC

Christophe Weber

Drug Manufacturers - Specialty & Generic

Healthcare

TKPHF

47029

JP

USD

https://www.takeda.com

81 3 3278 2111

N/A

0001395064

Liquidity Metrics

0.63

1.27

0.70

0.24

1.63

Sales & Valuation

$4.53T

1.93

1.10

11.14

500.69

Profitability

$119.84

$192.97B

4.26%

5.77%

2.61%

1.24%

P/E Metrics

44.93

0.58

0.58

Analyst Price Target & Rating

Neutral

3/5

5 Analysts

%

Poll Results

About Takeda Pharmaceutical Company Limited (OTC:TKPHF) Stock

Takeda Pharmaceutical Company Limited, an established global biopharmaceutical entity founded in 1781 and based in Tokyo, Japan, is comprehensively involved in the entire process of bringing new medicines to market. This includes the research, development, production, commercialization, and external licensing of its pharmaceutical products across a vast international footprint, encompassing Japan, the United States, Europe, Canada, Latin America, Russia, and other parts of Asia. The company concentrates its therapeutic endeavors on key medical areas such as digestive health (gastroenterology), rare disorders, treatments derived from blood plasma, cancer care (oncology), and neurological conditions. Its extensive portfolio features numerous well-known brands, including Entyvio, Takhzyro, Ve ... lcade, Livtencity, and Dexilant, among others. Takeda actively cultivates a wide-ranging network of strategic partnerships and collaborations. This includes out-licensing agreements, for example with Neurocrine Biosciences, Inc.; in-licensing deals and research collaborations with organizations like the University of Texas MD Anderson Cancer Center, Arrowhead Pharmaceuticals Inc., and Ovid Therapeutics Inc.; and joint research efforts with companies such as Crescendo Biologics and Skyhawk Therapeutics. Furthermore, Takeda maintains strategic alliances with entities like Evotec SE and KSQ Therapeutics, underscoring its commitment to external innovation.

Frequently Asked Questions

What is the current Takeda Pharmaceutical Company Limited (TKPHF) stock price?

Takeda Pharmaceutical Company Limited(OTC:TKPHF) stock price is $34.7 in the last trading session. During the trading session, TKPHF stock reached the peak price of $39.2 while $26.33 was the lowest point it dropped to. The percentage change in TKPHF stock occurred in the recent session was 0.0% while the dollar amount for the price change in TKPHF stock was $0.

TKPHF's industry and sector of operation?

The OTC listed TKPHF is part of Drug Manufacturers - Specialty & Generic industry that operates in the broader Healthcare sector.

Who are the executives of TKPHF?

Andrew S. Plump | President of Research & Development and Representative Director
So-Young Kim | CEO, President & Director
Christopher David O'Reilly | Global Head of Investor Relations & Global Finance
Haruhiko Hirate | Member of Management Board
Iwaaki Taniguchi | Senior Vice President of Corporate Finance & Controlling Department

How many employees does TKPHF have?

Number of TKPHF employees currently stands at 47029. TKPHF operates from 1-1, Nihonbashi-Honcho 2-chome, Tokyo, OS 103-8668, JP.

Link for TKPHF official website?

Official Website of TKPHF is: https://www.takeda.com

How do I contact TKPHF?

TKPHF could be contacted at phone #81 3 3278 2111 and can also be accessed through its website. TKPHF operates from 1-1, Nihonbashi-Honcho 2-chome, Tokyo, OS 103-8668, JP.

How many shares of TKPHF are traded daily?

The average number of TKPHF shares traded daily for last 3 months was 9.16K.

What is the market cap of TKPHF currently?

The market value of TKPHF currently stands at $55.2B with its latest stock price at $34.7